These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
366 related articles for article (PubMed ID: 34752156)
1. Assessment of SARS-CoV-2 Seroprevalence by Community Survey and Residual Specimens, Denver, Colorado, July-August 2020. Kugeler KJ; Podewils LJ; Alden NB; Burket TL; Kawasaki B; Biggerstaff BJ; Biggs HM; Zacks R; Foster MA; Lim T; McDonald E; Tate JE; Herlihy RK; Drobeniuc J; Cortese MM Public Health Rep; 2022; 137(1):128-136. PubMed ID: 34752156 [TBL] [Abstract][Full Text] [Related]
2. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201 [TBL] [Abstract][Full Text] [Related]
3. Comparison of SARS-CoV-2 seroprevalence estimates between commercial lab serum specimens and blood donor specimens, United States, September-December 2021. Kao S-YZ; Nycz E; Benoit TJ; Clarke KEN; Jones JM Microbiol Spectr; 2024 Aug; 12(8):e0012324. PubMed ID: 38869287 [TBL] [Abstract][Full Text] [Related]
4. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. Bajema KL; Wiegand RE; Cuffe K; Patel SV; Iachan R; Lim T; Lee A; Moyse D; Havers FP; Harding L; Fry AM; Hall AJ; Martin K; Biel M; Deng Y; Meyer WA; Mathur M; Kyle T; Gundlapalli AV; Thornburg NJ; Petersen LR; Edens C JAMA Intern Med; 2021 Apr; 181(4):450-460. PubMed ID: 33231628 [TBL] [Abstract][Full Text] [Related]
5. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148 [TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP; Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Seroprevalence Compared with Confirmed COVID-19 Cases among Children, Colorado, USA, May-July 2021. O'Brien SC; Cole LD; Albanese BA; Mahon A; Knight V; Williams N; Severson R; Burakoff A; Alden NB; Dominguez SR Emerg Infect Dis; 2023 May; 29(5):929-936. PubMed ID: 36972709 [TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study. Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Anand S; Montez-Rath M; Han J; Bozeman J; Kerschmann R; Beyer P; Parsonnet J; Chertow GM Lancet; 2020 Oct; 396(10259):1335-1344. PubMed ID: 32987007 [TBL] [Abstract][Full Text] [Related]
12. Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021-February 2022. Benoit TJ; Kim Y; Deng Y; Li Z; Harding L; Wiegand R; Deng X; Jones JM; Ronaldo I; Clarke KEN Public Health Rep; 2024; 139(4):501-511. PubMed ID: 38357883 [TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 seroprevalence in King County, WA-Cross-sectional survey, August 2020. Cowgill KD; Erosheva EA; Elder A; Miljacic L; Buskin S; Duchin JS PLoS One; 2022; 17(8):e0272783. PubMed ID: 35994500 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189 [TBL] [Abstract][Full Text] [Related]
15. Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19 Infection Among Outpatients in Virginia. Rogawski McQuade ET; Guertin KA; Becker L; Operario D; Gratz J; Guan D; Khan F; White J; McMurry TL; Shah B; Garofalo S; Southerland M; Bear K; Brush J; Allen C; Frayser A; Vokes R; Pershad R; Peake L; deFilippi C; Barackman K; Bearman G; Bidanset A; Farrell F; Trump D; Houpt ER JAMA Netw Open; 2021 Feb; 4(2):e2035234. PubMed ID: 33555331 [TBL] [Abstract][Full Text] [Related]